Vertex Pharmaceuticals Announces Results From Phase 2b AMPLIFIED Study Of Inaxaplin In People With Kidney Disease And Type-2 Diabetes; Treatment With Inaxaplin Led To Reduction In Urine Albumin To Creatinine Ratio Of -42.7% At Week 13 Compared To Baseline; Inaxaplin Was Generally Safe And Well Tolerated In Both Cohorts
Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.In this study, inaxaplin was evaluated as a 45 mg once-daily
Vertex tested a new kidney medicine called inaxaplin. The medicine reduced kidney protein leaking by 42.7% and seemed safe, which is good progress for sick patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.